Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
ZUNVEYL (BENZGALANTAMINE GLUCONATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
ZUNVEYL
NDA
Get alerts
BENZGALANTAMINE GLUCONATE | N218549 | ALPHA COGNITION INC
3 strengths
4 unique patents
0 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
DMF
Approvals
Label
Products
Patent Timeline
4 unique patents by expiration date
All strengths
EQ 5MG BASE
EQ 10MG BASE
EQ 15MG BASE
Expiring < 1yr (1)
Active (3)
Today
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
Today
9763953
Dec. 1, 2026
11795176
Jan. 13, 2042
12208167
Feb. 26, 2044
12551491
Jul. 23, 2045
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (3)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 5MG BASE
RLD
4 patents
0 exclusivities
▴
TABLET, DELAYED RELEASE;ORAL | Approved: Jul 26, 2024
Patents (4)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9763953
Dec 1, 2026
—
—
—
U-713
TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
—
11795176
Jan 13, 2042
—
Yes
—
U-713
TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
—
12208167
Feb 26, 2044
—
—
Yes
U-713
TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
—
12551491
Jul 23, 2045
—
—
—
U-713
TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE
—
#002 — EQ 10MG BASE
RLD
4 patents
0 exclusivities
▾
TABLET, DELAYED RELEASE;ORAL | Approved: Jul 26, 2024
#003 — EQ 15MG BASE
RLD
4 patents
0 exclusivities
▾
TABLET, DELAYED RELEASE;ORAL | Approved: Jul 26, 2024